Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized trial of nivolumab plus elotuzumab vs elotuzumab-based control in relapsed/refractory multiple myeloma
2015-005699-21Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab and elotuzumab in multiple myeloma (MM) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-free survival by investigator. Started May 2016; status: completed.
02
Drugs
nivolumabelotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2015-005699-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005699-21.